OXALIPLATIN PFIZER 5 mg/ml infuusiokonsentraatti, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

oxaliplatin pfizer 5 mg/ml infuusiokonsentraatti, liuosta varten

pfizer pfe finland oy - oxaliplatinum - infuusiokonsentraatti, liuosta varten - 5 mg/ml - oksaliplatiini

PARACETAMOL/CODEIN ORION 500 mg / 30 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

paracetamol/codein orion 500 mg / 30 mg tabletti

orion corporation - codeini phosphas hemihydricus,paracetamolum - tabletti - 500 mg / 30 mg - kodeiini ja parasetamoli

OXAPLAMYL 5 mg/ml infuusiokonsentraatti, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

oxaplamyl 5 mg/ml infuusiokonsentraatti, liuosta varten

mylan ireland limited mylan ireland limited - oxaliplatinum - infuusiokonsentraatti, liuosta varten - 5 mg/ml - oksaliplatiini

Ondansetron Kalceks 2 mg/ml injektio-/infuusioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

ondansetron kalceks 2 mg/ml injektio-/infuusioneste, liuos

as kalceks - ondansetron hydrochloride dihydrate - injektio-/infuusioneste, liuos - 2 mg/ml - ondansetroni

Pyrukynd Euroopan unioni - suomi - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Tibsovo Euroopan unioni - suomi - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiset aineet - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.